Introduction
============

Type 2 diabetes mellitus (T2DM) is a metabolic disease that occurs frequently mainly in the middle-aged and elderly period and accounts for above 90% of diabetes. Diabetes often leads to cardiovascular disease ([@b1-etm-0-0-6170]). The morbidity and mortality rates of T2DM complicated with coronary heart disease (CHD) are increasing. Approximately 70% of T2DM eventually die of cardiovascular and cerebrovascular diseases, and CHD is responsible for 50% of deaths ([@b2-etm-0-0-6170]). Occurrence and development mechanism of CHD in patients with T2DM is not clear yet. Increasing number of studies are conducted on insulin resistance (IR), oxidative stress, disorder of lipid metabolism, endothelial dysfunction, hypertension and inflammatory reaction ([@b3-etm-0-0-6170],[@b4-etm-0-0-6170]). It was shown that IR is a common pathophysiological change of metabolic syndrome, diabetes and atherosclerosis. When IR occurs, the concentration of inflammatory cytokines and inflammatory-sensitive proteins in the body will increase, leading to the inflammatory reaction in the arterial wall ([@b5-etm-0-0-6170]). This study mainly explored the correlation of IR and leptin with inflammatory factors and vascular endothelial injury in patients with T2DM + CHD with the expectation of providing a novel diagnostic indicator for of diabetes complicated with CHD.

Patients and methods
====================

### General data

One hundred and fifty normal patients, 150 patients with T2DM and 150 patients with T2DM + CHD were selected from Xi\'an No. 5 Hospital (Xi\'an, China). General data of the three groups of patients are given in [Table I](#tI-etm-0-0-6170){ref-type="table"}.

### Inclusion and exclusion criteria

Inclusion criteria: Patients with T2DM: Diagnostic criteria for diabetes established by WHO in 1999 was taken as the reference of diagnosis; patients with T2DM + CHD: Patients that had diabetes mellitus complicated with CHD and the diagnostic criteria established by International Heart Association and WHO in 1979 were taken for the determination of CHD; normal group: Patients that were free from diabetes mellitus and CHD.

Exclusion criteria: i) Patients with type 1 diabetes mellitus or diabetes mellitus with complications; patients with resistant or primary hypertension or patients with hypertension with left ventricle hypertrophy; patients with peripheral vascular diseases; patients who were taking glucose-reducing, lipid-decreasing and antihypertensive drugs or using insulin for treatment. ii) Patients with hyperglycemia caused by other reasons or patients with acute or chronic inflammatory disease; patients with severe chronic complications such as heart failure and left ventricular ejection fraction \<50%; patients who suffered from cerebrovascular accident. iii) Patients with endocrine diseases such as hyperthyroidism and gout; pregnant women; patients with autoimmune diseases; patients with family histories of infectious diseases and hereditary diseases. All the patients or their families signed the informed consent form and this study was approved by the Ethics Committee of Xi\'an No. 5 Hospital.

### Study methods

The venous blood specimens were taken from the patients on an empty stomach in the morning. Sex, age, fasting plasma glucose (FPG), waist-to-hip ratio (WHR), body mass index (BMI), blood lipid, systolic blood pressure (SBP) and diastolic blood pressure (DBP), of all the subjects were measured or collected, in which, BMI = body mass (kg)/height (m^2^). Plasma glucose was measured by glucose oxidase method with Roche glucometer; blood lipid was measured by enzymatic method. The reagent was provided by Zhejiang Dongou Biochemical Co., Ltd., (Zhejiang, China) and the instrument used was 7170S fully-automatic biochemical analyzer provided by Hitachi, Ltd. (Tokyo, Japan); hemoglobin A1c (HbA1c) was measured by high-performance liquid chromatography (the kit was provided by Bio-Rad Laboratories, Inc., Hercules, CA, USA); fasting insulin (FINS) was measured by chemoluminescence immunoassay (the kit was provided by China Institute of Atomic Energy, Beijing, China and the instrument used was Abbotti 1000SR fully-automatic chemiluminescence analyzer provided by Abbott Pharmaceutical Co. Ltd., Lake Bluff, IL, USA); plasma leptin levels were determined by double-antibody sandwich method (plasma leptin kits were provided by Shenzhen Yinuojin Biotechnology Co., Ltd., and microplate reader was provided by Bio-Rad Laboratories, Inc.); high-sensitivity C-reactive protein (hs-CRP) was detected by turbidimetry (the kit was provided by DADE Corporation and the instrument used was BN ProSpec, a special Pr analyzer); von Willebrand factor (vWF), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected by double-antibody sandwich enzyme-linked immunosorbent assay. Endothelin (ET-1) kits were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China) and other kits were provided by Beijing United Bowei Biotechnology Co., Ltd., (Beijing, China). Homeostasis model assessment-insulin resistance (HOMA-IR) = FINS/22.5 ([@b6-etm-0-0-6170]) and insulin resistance index (IRI) = FPG (mmol/l)xFINS (mU/l)/22.5^\[2\]^ were used to evaluate IR.

### Statistical analysis

All the data were processed using Statistical Product and Service Solutions (SPSS) version 22.0 (IBM Corp., Armonk, NY, USA) and the data that were in line with normal distribution are expressed as mean ± SD. The t-test was conducted for comparison between groups and the non-normally-distributed measurement data were expressed as median (interquartile range). Non-parametric rank sum test was conducted for the comparison between groups. The χ^2^ test was adopted for comparison of rate, and variance analysis was used for comparison of the mean among multiple groups. One-way analysis of variance was used for comparison between two groups and the post-hoc test used was Tukey test. P\<0.05 was considered to indicate a statistically significant difference. Pearson\'s correlation test was used for the analysis on the correlation of IR and leptin with inflammatory factors and vascular endothelial injury.

Results
=======

### Comparisons of general data and relevant biochemical indexes among the three groups

General data such as constituent ratio of age and sex had no statistical significance (P\>0.05), and they were comparable. The differences of the comparison between the T2DM group (patients with T2DM) and the normal group in terms of biochemical indexes including FPG, DBP, FINS, HbA1c, HOMA-IR, low-density lipoprotein cholesterol (LDL-C), ET-1, TNF-α, IL-6 and vWF had statistical significance (P\<0.05). The differences of the comparison between the T2DM and the normal groups and that between the T2DM+CHD and the T2DM groups in terms of BMI, FPG, SBP, DBP, HbA1c, HOMA-IR, high-density lipoprotein cholesterol (HDL-C), hs-CRP, leptin, ET-1, TNF-α, IL-6 and vWF had statistical significance (P\<0.05). The difference of the comparison of WHR and FINS between the group of T2DM + CHD and the normal groups and that between the T2DM and the normal groups had statistical significance (P\<0.05), while the difference of the comparison between the T2DM+CHD and the T2DM groups had no statistical significance (P\>0.05). The differences of the comparison among the groups in terms of the remaining biochemical indexes had no statistical significance (P\>0.05). Specific details are given in [Table I](#tI-etm-0-0-6170){ref-type="table"}.

### Analysis on correlation of IR and leptin with inflammatory factors and vascular endothelial function

Pearson correlation analysis of IRI with IL-6, TNF-α, hs-CRP and vascular endothelial function: IRI was positively correlated with IL-6, TNF-α and hs-CRP, and it had no direct correlation with vascular endothelial function ([Table II](#tII-etm-0-0-6170){ref-type="table"}).

Pearson correlation analysis of leptin with hs-CRP, IL-6, TNF-α and vascular endothelial function: Leptin revealed a positive correlation with hs-CRP, IL-6 and TNF-α, but was negatively correlated with vascular endothelial function ([Table III](#tIII-etm-0-0-6170){ref-type="table"}).

Discussion
==========

T2DM is a relatively common chronic inflammatory and metabolic disease, which can impair vascular endothelial function ([@b7-etm-0-0-6170]) through glucose toxicity, lipotoxicity and inflammatory mediators. Increasing number of patients with T2DM are complicated with CHD. This study explored the correlation of IR and leptin with inflammatory factors and vascular endothelial function.

Participants in this study were selected strictly as per the inclusion and exclusion criteria, which ensured the quality of the study. The sample size was relatively large, which increased credibility and persuasion of the results of this study. The study was approved by the Ethics Committees of the Xi\'an No. 5 Hospital.

The mechanism of concurrence of CHD for T2DM is not clear yet. Lee *et al* believed that there is leptin resistance in T2DM patients complicated with CHD ([@b8-etm-0-0-6170]); el-Mesallamy *et al* ([@b9-etm-0-0-6170]), Pfützner and Forst ([@b10-etm-0-0-6170]) and Barzilay *et al* ([@b11-etm-0-0-6170]) stated that there is inflammatory reaction in T2DM patients complicated with CHD; Torimoto *et al* ([@b12-etm-0-0-6170]) and Zaghloul *et al* ([@b13-etm-0-0-6170]) considered that vascular endothelial function is impaired for T2DM patients complicated with CHD. IR is an important mechanism for the pathogenesis of T2DM and it is closely related with the occurrence and development of CHD. Leptin mainly has the function of regulating carbohydrate and lipid metabolism, insulin secretion and the synthesis of fat cells, thus reducing the weight ([@b4-etm-0-0-6170]). Resistance of insulin and leptin help to promote the secretion of leptin ([@b8-etm-0-0-6170]). Leptin receptors were also found in coronary endothelial cells ([@b14-etm-0-0-6170]). hs-CRP can inhibit the combination of leptin with its receptors, thereby inhibiting the effect of leptin ([@b15-etm-0-0-6170]). Resistance and insufficient secretion of insulin promote islet cells to secret TNF-α and IL-6, thus aggravating IR ([@b8-etm-0-0-6170]). vWF is a glycoprotein that is secreted by endothelial cells, which can mediate the adhesion of platelets on the vascular injury sites. Our study indicated that the difference of the comparison of HOMA-IR, hs-CRP, leptin, ET-1, TNF-α, IL-6 and vWF between the T2DM and the normal groups and that between the group of T2DM + CHD and the T2DM groups had statistical significance, which was consistent with previous study results ([@b16-etm-0-0-6170],[@b17-etm-0-0-6170]). The T2DM group and the group of T2DM + CHD: HOMA-IR was positively correlated with hs-CRP, IL-6 and TNF-α, and it had no direct correlation with vascular endothelial function, which was consistent with other study results ([@b8-etm-0-0-6170],[@b18-etm-0-0-6170],[@b19-etm-0-0-6170]); leptin was positively correlated with IL-6, TNF-α and hs-CRP, and it was negatively correlated with vascular endothelial function. The correlation of leptin with hs-CRP may be related with the function of leptin in activating protein kinase C ([@b18-etm-0-0-6170]), which is dose-dependent ([@b20-etm-0-0-6170]). Leptin has no obvious correlation with hs-CRP for normal persons. Only high concentration of leptin has such an effect. Leptin may cause vascular inflammatory response, thus participating in the occurrence and development of T2DM + CHD. Kosztáczky *et al* ([@b21-etm-0-0-6170]) and Maya-Monteiro *et al* ([@b22-etm-0-0-6170]) found in their studies that the higher the concentration of plasma leptin is, the more severe the degree of coronary artery disease will be. This study explored the correlations between IR, leptin and inflammatory factors and vascular endothelial injury in patients with T2DM + CHD. Previous reports only examined the relationship between some of these factors in patients with type 2 diabetes and CHD. Such as the relationship between leptin resistance and vascular endothelial function, leptin resistance leads to increased plasma leptin levels, which in turn cause endothelial dysfunction ([@b23-etm-0-0-6170],[@b24-etm-0-0-6170]). Although our study examined a number of indicators in patients with T2DM combined with with CHD and conducted correlation analyses, correlations between these indicators in T2DM patients without CHD were not discussed. Therefore, the specific mechanism of type 2 diabetes combined with CHD, and these indicators in type 2 diabetes without CHD still needed to be further studied.

In conclusion, TNF-α, hs-CRP, IL-6 and leptin are involved in the occurrence and development of CHD in patients with T2DM. IR may have no direct correlation with the occurrence and development of CHD in patients with T2DM. The detection of inflammatory factors such as hs-CRP, IL-6 and TNF-α is of great clinical significance in evaluating the occurrence and development of CHD in patients with diabetes mellitus.
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###### 

Comparison of general data and test results of biochemical indexes among the groups (mean ± SD).

                               Groups                                                                      
  ---------------------------- -------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------
  No.                          150            150                                                          150
  Age (years)                  50.40±8.56     51.69±7.78                                                   52.40±8.42
  Sex (n)                                                                                                  
    Male                       75             76                                                           74
    Female                     75             74                                                           76
  BMI (kg/m^2^)                23.42±3.56     23.78±3.24                                                   28.12±3.13^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  FPG (mmol/l)                 5.04±0.62      9.35±1.24^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^      13.32±1.62^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  WHR                          0.82±0.04      0.96±0.04^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^      0.97±0.06^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^
  SBP (mm Hg)                  124.80±14.36   130.96±12.56                                                 161.42±17.56^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  DBP (mm Hg)                  80.14±9.08     87.54±9.13^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^     94.43±10.13^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  FINS (mU/l)                  5.76±0.63      11.28±2.05^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^     15.72±2.64^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^
  HbA1c (%)                    5.31±0.33      8.29±0.51^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^      10.88±2.01^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  HOMA-IR                      1.38           2.79                                                         3.52
                               (0.52--1.84)   (0.84--3.41)^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^   (1.72--4.86)^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  Triglyceride (mmol/l)        1.45±0.42      1.61±0.46                                                    1.68±0.56
  Total cholesterol (mmol/l)   4.88±0.87      4.90±1.08                                                    4.74±1.10
  HDL-C (mmol/l)               1.43±0.27      1.31±0.21                                                    0.73±0.18^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  LDL-C (mmol/l)               2.83±0.79      3.72±0.88^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^      3.69±0.93^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^
  Lipoprotein (a) (mg/l)       4.38±0.52      4.52±1.21                                                    5.43±0.96^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  hs-CRP (mg/l)                5.72±2.22      5.89±3.43                                                    16.28±19.62^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  Leptin (µg/l)                1.86±0.34      2.08±0.54^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^      2\. 42± 0.62^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  ET-1 (mmol/l)                35±9           49±13^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^          61±19^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  TNF-α (ng/ml)                0.25±0.12      0.41±0.26^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^      0.73±0.38^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  IL-6 (ng/ml)                 0.33±0.28      0.73±0.24^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^      1.08±0.32^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^
  vWF (%)                      112.65±20.62   130.54±22.64^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"}^   150.68±24.76^[a](#tfn1-etm-0-0-6170){ref-type="table-fn"},[b](#tfn2-etm-0-0-6170){ref-type="table-fn"}^

P\<0.05, compared with normal group

P\<0.05, compared with T2DM group. T2DM, type 2 diabetes mellitus; T2DM+CHD, type 2 diabetes mellitus complicated with coronary heart disease; BMI, body mass index; FPG, fasting plasma glucose; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FINS, fasting insulin; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; ET-1, endothelin; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; HOMA-IR, homeostasis model assessment-insulin resistance; vWF, von Willebrand factor.

###### 

Correlation of IRI with hs-CRP, IL-6, TNF-α, ET-1 and vWF.

  Variable   hs-CRP   IL-6    TNF-α   ET-1    vWF
  ---------- -------- ------- ------- ------- -------
  r          0.521    0.359   0.386   0.058   0.047
  P-value    0.001    0.001   0.001   0.734   0.812

IRI, insulin resistance index; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; ET-1, endothelin; vWF, von Willebrand factor.

###### 

Correlation of leptin with hs-CRP, IL-6, TNF-α, ET-1 and vWF.

  Variable   hs-CRP   IL-6    TNF-α   ET-1    vWF
  ---------- -------- ------- ------- ------- -------
  r          0.305    0.259   0.429   0.366   0.471
  P-value    0.001    0.002   0.001   0.001   0.001

hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; ET-1, endothelin; vWF, von Willebrand factor.
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